Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C19H20F2N4O4 |
Molar mass | 406.390 g·mol−1 |
3D model ( JSmol) | |
| |
|
Pamapimod is an investigational drug which is being evaluated for the treatment of autoimmune diseases. It is a p38 mitogen-activated protein kinase inhibitor. [1] It has been evaluated in a phase 2 clinical trial for the treatment of rheumatoid arthritis, but was found not to be effective. [2] [3] It has subsequently been investigated as a possible treatment for osteoarthritis. [4] [5]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C19H20F2N4O4 |
Molar mass | 406.390 g·mol−1 |
3D model ( JSmol) | |
| |
|
Pamapimod is an investigational drug which is being evaluated for the treatment of autoimmune diseases. It is a p38 mitogen-activated protein kinase inhibitor. [1] It has been evaluated in a phase 2 clinical trial for the treatment of rheumatoid arthritis, but was found not to be effective. [2] [3] It has subsequently been investigated as a possible treatment for osteoarthritis. [4] [5]